Posted on Leave a comment

Vivus Plunges Most Ever After U.S. Review of Qnexa

More info…
Vivus Inc. shares plunged the most ever in New York trading the day after U.S. reviewers recommended against approval of its Qnexa diet pill, a decision that analysts say may threaten makers of competing drugs.

national opiate hotline

Leave a Reply

Your email address will not be published.